Literature DB >> 30992185

Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing.

Matthew S Ning1, Ann H Klopp1, Anuja Jhingran1, Lilie L Lin1, Patricia J Eifel1, Sastry Vedam1, Ann A Lawyer1, Nicholas D Olivieri1, Alexis B Guzman2, James R Incalcaterra2, Shane M Mesko1, Todd A Pezzi1, David R Boyce-Fappiano1, Simona F Shaitelman1, Steven J Frank1, Nikhil G Thaker3.   

Abstract

PURPOSE: The purpose of this study was to quantify the cost of resources required to deliver adjuvant radiation therapy (RT) for high- to intermediate-risk endometrial cancer using time-driven activity-based costing (TDABC). METHODS AND MATERIALS: Comparisons were made for three and five fractions of vaginal cuff brachytherapy (VCB), 28 fractions of intensity-modulated radiation therapy (IMRT), and combined modality RT (25-fraction IMRT followed by 2-fraction VCB). Process maps were developed representing each phase of care. Salary and equipment costs were obtained to derive capacity cost rates, which were multiplied by process times and summed to calculate total costs. Costs were compared with 2018 Medicare physician fee schedule reimbursement.
RESULTS: Full cycle costs for 5-fraction VCB, IMRT, and combined modality RT were 42%, 61%, and 93% higher, respectively, than for 3-fraction VCB. Differences were attributable to course duration and number of fractions/visits. Accumulation of cost throughout the cycle was steeper for VCB, rising rapidly within a shorter time frame. Personnel cost was the greatest driver for all modalities, constituting 76% and 71% of costs for IMRT and VCB, respectively, with VCB requiring 74% more physicist time. Total reimbursement for 5-fraction VCB was 40% higher than for 3-fractions. Professional reimbursement for IMRT was 31% higher than for 5-fraction VCB, vs. IMRT requiring 43% more physician TDABC than 5-fraction VCB.
CONCLUSIONS: TDABC is a feasible methodology to quantify the cost of resources required for delivery of adjuvant IMRT and brachytherapy and produces directionally accurate costing data as compared with reimbursement calculations. Such data can inform institution-specific financial analyses, resource allocation, and operational workflows.
Copyright © 2019 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HDR brachytherapy; Health care value; TDABC; Vaginal cuff brachytherapy

Year:  2019        PMID: 30992185     DOI: 10.1016/j.brachy.2019.03.003

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  4 in total

1.  Time-driven activity-based costing of a novel form of CT-guided high-dose-rate brachytherapy intraoperative radiation therapy compared with conventional breast intraoperative radiation therapy for early stage breast cancer.

Authors:  Greg Suralik; Sonali Rudra; Sunil W Dutta; Jialu Yu; Jason C Sanders; Michael D Schad; Einsley-Marie Janowski; Lucy Su; Bruce Libby; Shayna L Showalter; Jennifer M Lobo; Timothy N Showalter
Journal:  Brachytherapy       Date:  2020-03-28       Impact factor: 2.362

2.  Evaluating single-institution resource costs of consolidative radiotherapy for oligometastatic non-small cell lung cancer using time-driven activity-based costing.

Authors:  Todd A Pezzi; Matthew S Ning; Nikhil G Thaker; David Boyce-Fappiano; Olsi Gjyshi; Nicholas D Olivieri; Alexis B Guzman; James R Incalcaterra; Shane Mesko; Saumil Gandhi; Stephen Chun; Chad Tang; Steven J Frank; Daniel R Gomez
Journal:  Clin Transl Radiat Oncol       Date:  2020-05-30

3.  Cost Analysis of Selected Radiotherapeutic Modalities for Prostate Cancer Treatment-Czech Republic Case Study for the Purposes of Hospital Based HTA.

Authors:  Petra Hospodková; Tomáš Husár; Barbora Klíčová; Lucie Severová; Karel Šrédl; Roman Svoboda
Journal:  Healthcare (Basel)       Date:  2021-01-19

4.  The Case for Brachytherapy: Why It Deserves a Renaissance.

Authors:  Vonetta M Williams; Jenna M Kahn; Nikhil G Thaker; Sushil Beriwal; Paul L Nguyen; Douglas Arthur; Daniel Petereit; Brandon A Dyer
Journal:  Adv Radiat Oncol       Date:  2020-11-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.